Inovio Pharmaceuticals, Inc.
Cancer vaccines targeting PRAME and uses thereof

Last updated:

Abstract:

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.

Status:
Grant
Type:

Utility

Filling date:

13 Dec 2018

Issue date:

24 May 2022